204 related articles for article (PubMed ID: 36845145)
41. H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma.
Fan T; Zhu M; Muhammad S; Xiao C; Li S; Tian H; Liu Y; Xue L; Zheng B; Li C; He J
Respir Res; 2023 May; 24(1):122. PubMed ID: 37131252
[TBL] [Abstract][Full Text] [Related]
42. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
[TBL] [Abstract][Full Text] [Related]
43. Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications.
Hijazo-Pechero S; Alay A; Cordero D; Marín R; Vilariño N; Palmero R; Brenes J; Montalban-Casafont A; Nadal E; Solé X
Mol Oncol; 2024 Feb; 18(2):453-470. PubMed ID: 37943164
[TBL] [Abstract][Full Text] [Related]
44. Characteristics of the immunogenicity and tumor immune microenvironment in
Wang Q; Mao Z; Li W; Wang S; Wang L; Chen L; Yang Z; Fu X; Jiang P; Bai Y; Xu L; Zhang S; Hou Y; Jia X; Jiang L; Liu M; Zhang G; Jiang Y; Guo H
Front Immunol; 2022; 13():1042072. PubMed ID: 36591290
[TBL] [Abstract][Full Text] [Related]
45. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
[TBL] [Abstract][Full Text] [Related]
46. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
47. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
48. LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response.
Huang J; Yuan L; Huang W; Liao L; Zhu X; Wang X; Li J; Liang W; Wu Y; Liu X; Yu D; Zheng Y; Guan J; Zhan Y; Liu L
Front Immunol; 2022; 13():1064874. PubMed ID: 36505456
[TBL] [Abstract][Full Text] [Related]
49. A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma.
Zhang Y; Wang Y; Chen J; Xia Y; Huang Y
Front Immunol; 2023; 14():1183230. PubMed ID: 37671155
[TBL] [Abstract][Full Text] [Related]
50. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
51. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
52. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
53. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.
Zhang H; Lin J; Yahaya BH
J Cancer Res Clin Oncol; 2024 Jan; 150(2):44. PubMed ID: 38281298
[TBL] [Abstract][Full Text] [Related]
55. Multi-omics immune regulatory mechanisms in lung adenocarcinoma metastasis and survival time.
Liu D; Yao L; Ding X; Zhou H
Comput Biol Med; 2023 Sep; 164():107333. PubMed ID: 37586202
[TBL] [Abstract][Full Text] [Related]
56. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
57. Computational identification and experimental verification of a novel signature based on SARS-CoV-2-related genes for predicting prognosis, immune microenvironment and therapeutic strategies in lung adenocarcinoma patients.
Wang Y; Xu Y; Deng Y; Yang L; Wang D; Yang Z; Zhang Y
Front Immunol; 2024; 15():1366928. PubMed ID: 38601163
[TBL] [Abstract][Full Text] [Related]
58. Identification of hypoxia-related gene signatures based on multi-omics analysis in lung adenocarcinoma.
Luo Q; Li X; Meng Z; Rong H; Li Y; Zhao G; Zhu H; Cen L; Liao Q
J Cell Mol Med; 2024 Jan; 28(2):e18032. PubMed ID: 38013642
[TBL] [Abstract][Full Text] [Related]
59. A novel methionine metabolism-related signature predicts prognosis and immunotherapy response in lung adenocarcinoma.
Chang QH; Zhang YC; Zhang DY; Mao T; Chang R; Wang N; Ye Y; Xu ZJ
Aging (Albany NY); 2023 May; 15(9):3498-3523. PubMed ID: 37179124
[TBL] [Abstract][Full Text] [Related]
60. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
